Work

From bench to body: In vivo CAR engineering in the clinic

Year: 2025

Type: article

Abstract: In vivo CAR engineering is an emerging therapeutic platform for cancer and autoimmune diseases. Enabled by advanced delivery systems such as immune-evasive lentiviral vectors and targeted lipid nanoparticles, this strategy has progressed to early clinical testing, showing initial safety and efficacy. Here, key opportunities and translational hurdles are critically discussed. In vivo CAR engineering is an emerging therapeutic platform for cancer and autoimmune diseases. Enabled by advanced delivery systems such as immune-evasive lentiviral vectors and targeted lipid nanoparticles, this strategy has progressed to early clinical testing, showing initial safety and efficacy. Here, key opportunities and translational hurdles are critically discussed.

Source: Cell Reports Medicine

DOI: 10.1016/j.xcrm.2025.102337

Authors: Yan-Ruide Li, Lili Yang

Institutions: University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $5,620